Prepulse inhibition (PPI) is the reduction in the startle response caused by a low intensity non-startling stimulus (the prepulse) which is presented shortly before the startle stimulus and is an operational measure of sensorimotor gating. PPI is impaired in psychiatric disorders such as schizophrenia. Ketamine, a non-competitive N-methyl-D-aspartate antagonist has been shown to induce schizophrenia-Like behavioural changes in humans and PPI deficits in rats, which can be reversed by antipsychotics. Thus, ketamine-induced PPI deficits in rats may provide a translational model of schizophrenia. The aim of this study was to investigate the effects of antipsychotic drugs and drugs known to alter the glutamate system upon ketamine-induced PPI deficits in rats. Rats were habituated to the PPI procedure [randomized trials of either pulse alone (110 dB/50 ms) or prepulse + pulse (80 dB/10 ms)]. Animals were assigned to pre-treatments based on the level of PPI on the last habituation test and balanced across startle chambers. Ketamine (1—10 mg/kg s.c; 15 min ptt) increased startle ampLitude and induced PPI deficits at 6 and 10 mg/kg. PPI deficits induced by ketamine at 6 mg/kg were not attenuated by clozapine (2.5—10 mg/kg s.c.; 60 min ptt), risperidone (0.1—1 mg/kg i.p.; 60 min ptt), haloperidoL (0.1—1 mg/kg i.p.; 60 min ptt), lamotrigine (3—30 mg/kg p.o.; 60 min ptt), or SB-271046-A (5—20 mg/kg p.o.; 2 hour ptt) nor potentiated by 2-methyl-6-(phenylethynyl)-pyridine (3—10 mg/kg i.p.; 30 min ptt). These results suggest that under these test conditions ketamine-induced PPI deficits in rats is relatively insensitive and does not represent a translational model for drug discovery in schizophrenia.
Abel K.M. , Allin M P G , Hemsley D.R. , Geyer M.A. (2003) Low dose ketamine increases prepulse inhibition in healthy men . Neuropharmacology44: 729—737
2.
Anand A. , Charney D.S. , Oren D.A. , Berman R.M. , Hu X.S. , Cappiello A. , Krystal J.H. (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine . Arch. Gen. Psychiatry57: 270—276
3.
Bolino F. , DiMichele V. , DiCocco L. , Manna V. , Daneluzzo E. , Casacchia M. (1994) Sensorimotor gating and habituation evoked by electro-cutaneous stimulation in schizophrenics. BiologicalPsychiatry36: 670—679
4.
Braff D.L. (1989) Sensory input deficits and negative symptoms in schizophrenic patients . American Journal of Psychiatry146: 1006—1011
5.
Braff D.L. , Geyer M.A. (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Archives ofGeneral Psychiatry47: 181—188
6.
Braff D.L. , Grillon C. , Geyer M.A. (1992) Gating and habituation of the startle reflex in schizophrenic patients. Archives ofGeneral Psychiatry49: 206—215
7.
Braff D.L. , Swerdlow N.R. , Geyer M.A. (1995) Gating and habituation deficits in the schizophrenia disorders . Clinical Neuroscience3: 131—139
8.
Brody S.A. , Geyer M.A. , Large C.H. (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice . Psychopharmacology169: 240—246
9.
Brody S.A. , Dulawa S.C. , Conquet F. , Geyer M.A. (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. MolecularPsychiatry9: 35—41
10.
Bromidge S.M. , Brown A.M. , Clarke S.E. , Dodgson K. , Gager T. , Grassam H.L. , Jeffrey P.M. , Joiner G.F. , King F.D. , Middlemiss D.N. , Moss S.F. , Newman H. , Riley G. , Routledge C. , Wyman P. (1999) 5-Chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A potent, selective and orally bioavailable 5-HT6 receptor antagonist . J Med Chem.42: 202—205
11.
Cilia J. , Reavill C. , Hagan J.J. , Jones D N C (2001) Long-term evaluation of isolation-reared prepulse inhibition deficits in rats . Psychopharmacology156: 327—337
12.
Dawson L.A. , Nguyen H.Q. , Li P. (2001) The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus . Neuropsychopharmacology25: 662—668
13.
Devon R.S. , Anderson S. , Teague P.W. , Muir W.J. , Murray V. , Pelosi A.J. , Blackwood D H R , Porteous D.J. (2001) The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. MolecularPsychiatry6: 311—314
14.
Dirks A. , Groenink L. , Westphal K G C , Olivier J D A , Verdouw P.M. , van der Gugten J. , Geyer M.A. , Olivier B. (2003) Reversal of startle gating deficits in transgenic mice overexpressing corticotrophin-releasing factor by antipsychotic drugs . Neuropsychopharmacology28: 1790—1798
15.
Duncan E.J. , Madonick S.H. , Parwani A. , Angrist B. , Rajan R. , Chakravorty S. , Efferen T.R. , Szilagyi S. , Stephanides M. , Chappell P.B. , Gonzenbach S. , Ko G.N. , Rotrosen J.P. (2001) Clinical and sensorimotor gating effects of ketamine in normals . Neuropsychopharmacology25: 72—83
16.
Feifel D. , Priebe K. (1999) The effects of subchronic haloperidol on intact and dizocilpine-disrupted sensorimotor gating . Psychopharmacology146: 175—179
17.
Frederick J.A. , Meador-Woodruff J.H. (1999) Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in the rat brain . Schizophr Res38: 7—12
18.
Gartlon, J. , Cilia, J. , Shilliam, C.S. , Staveley, S.M. , Dawson, L.A. , Jones, D N C (2005) Behavioural and neurochemical investigation of a putative model of schizophrenia: Brattleboro rats . Schizophrenia Bulletin, 31: 299
19.
Geyer M.A. , Krebs-Thomson K. , Braff D.L. , Swerdlow, N.R. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review . Psychopharmacology156: 117—54
20.
Hatcher P.D. , Brown V.J. , Tait D.S. , Bate S. , Overend P. , Hagan J.J. , Jones D N C (2005) 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats . Psychopharmacology181: 253—259
21.
Henry S.A. , Lehmann-Masten V. , Gasparini F. , Geyer M.A. , Markou A. (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity . Neuropharmacology43: 1199—1209
22.
Hoffman H.S. , Ison J.R. (1980) Reflex modification in the domain of startle: I. Some empirical findings and their implication for how the nervous system processes sensory input . Psychol Rev87: 175—189
23.
Idris N.F. , Repeto P. , Neill J.C. , Large C.H. (2005) Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat . Psychopharmacol179: 336—348
24.
Keith V.A. , Mansbach R.S. , Geyer M.A. (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle . Biol. Psychiatry30: 557—566
25.
King M.V. , Sleight A.J. , Woolley M.L. , Topham I.A. , Marsden C.A. , Fone K C F (2004) 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism . Neuropharmacology47: 195—204
26.
Kinney G.G. , Burno M. , Campbell U.C. , Hernandez L.M. , Rodriguez D. , Bristow L.J. , Conn P.J. (2003) Metabotropic glutamate subtype 5 receptors modulate Locomotor activity and sensorimotor gating in rodents . JPET306: 116—123
27.
Kinney G.G. , O'Brien J.A. , Lemaire W. , Burno M. , Bickel D.J. , Clements M.K. , Chen T. , Wisnoski D.D. , Lindsley C.W. , Tiller P.R. , Smith S. , Jacobson M.A. , Sur C. , Duggan M.E. , Pettibone D.J. , Conn P.J. , Williams D.L. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models . JPET313: 199—206
28.
Krystal J.H. , Karper L.P. , Seibyl J.P. , Freeman G.K. , Delaney R. , Bremner J.D. , Heninger G.R. , Bowers M.B. , Charney D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, Ketamine, in humans . Arch Gen Psychiatry51: 199—214
29.
Krystal J.H. , D'Souza D.C. , Karper L.P. , Bennent A. , Abi-Dargham A. , Abi-Saab D. , Cassello K. , Bowers M.B. , Vegso S. , Heninger G.R. , Charney D.S. (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans . Psychopharmacology145: 193—204
30.
Krystal J H, D'Souza , Mathalon D. , Perry E. , Belger A. , Hoffman R. (2003) NMDA receptor antagonist effects, cortical glutamatergic function and schizophrenia: toward a paradigm shift in medication development . Psychopharmacol169: 215—233
31.
Large C.H. , Webster E.L. , Goff D.C. (2005) The potential role of lamotrigine in schizophrenia . Psychopharmacology181: 415—436
32.
Malhotra A.K. , Adler C.M. , Kennison S.D. , Elman I. , Pickar D. , Breier A. (1997) Clozapine blunts N-Methyl-D-Aspartate antagonist induced psychosis: A study with ketamine . Biol. Psychiatry42: 664—668
33.
Mansbach R.S. , Geyer M.A. , Braff D.L. (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat . Psychopharmacology94: 507—514
34.
Mansbach R.S. , Carver J. , Zorn S.H. (2001) Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone . Pharmacology, Biochemistry and Behaviour69: 535—542
35.
Meltzer H.Y. , Li Z. , Kaneda Y. , Ichikawa J. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in NeuroPsychopharmacology and BiologicalPsychiatry27: 1159—1172
36.
Morris B.J. , Cochran S.M. , Pratt J.A. (2005) PCP: from pharmacology to modelling schizophrenia. Current Opinion in Pharmacology5: 101—106
37.
Oranje B. , Gispen-de Wied C C. , Verbaten M N. , Kahn R S. (2002) Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidolBio Psychiatry52: 887—895
38.
Parwani A. , Duncan E.J. , Bartlett E. , Madonick S.H. , Efferen T.R. , Rajan R. , Sanfilipo M. , Chappell P.B. , Chakravorty S. , Gonzenbach S. , Ko G.N. , Rotrosen J.P. (2000) Impaired prepulse inhibition of acoustic startle in schizophrenia. BiologicalPsychiatry47: 662—669
39.
Pietraszek M. , Ossowska K. (1998) Chronic treatment with haloperidol diminishes the phencyclidine-induced sensorimotor gating deficit in rats . Naunyn-Schmiedeberg's Arch Pharmacol357: 466—471
40.
Pietraszek M. , Rogoz Z. , Wolfarth S. , Ossowska K. (2004) Opposite influence of MPEP, an mGluR5 antagonist, on the locomotor hyperactivity induced by PCP and Amphetamine. Journal of Physiology andPharmacology55: 587—593
41.
Pouzet B. , Didriksen M. , Arnt J. ( 2002) Effects of the 5-HT6 antagonist, SB-271046, in animal models for schizophrenia . Pharmacol Biochem Behav71: 635—643
42.
Reavill C. , Taylor S.G. , Wood M.D. , Ashmeade T. , Austin N.E. , Avenell K.Y. , Boyfiled I. , Branch C.L. , Cilia J. , Coldwell M.C. , Hadley M.S. , Hunter A.J. , Jeffrey P. , Jewett F. , Johnson C.N. , Jones D N C , Medhurst A.D. , Middlemiss D.N. , Nash D.J. , Riley G.J. , Routledge, Stemp G , Thewlis K.M. , Trail B. , Vong A K K , Hagan J. (2000). Pharmacological actions of a novel high affinity and selective dopamine D3 receptor antagonist. SB-277011-A . J Pharmacol Exp Ther294: 1154—1165
43.
Rogers D.C. , Hagan J.J. (2001) 5-HT6 receptor antagonists enhance retention of a water maze task in the rat . Psychopharmacology158: 114—119
44.
Roth B.L. , Criago S.C. , Choudhary M.S. , Uluer A. , Monsma F.J. , Shen Y. , Meltzer H.Y. , Sibley D.R. (1994) Binding of typical and atypical antipsychotic agents to 5-HT6 and 5-HT7 receptors . J Pharmacol Exp Ther268: 1403—1410
45.
Roth B.L. , Sheffler D.J. , Kroeze W.K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews , Drug Discovery3: 353—359
46.
Routledge C. , Bromidge S.M. , Moss S.F. , Price G.W. , Hirst W. , Newman H. , Riley G. , Gager T. , Stean T. , Upton N. , Clarke S.E. , Brown A.M. , Middlemiss D.N. (2000) Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist . British Journal of Pharmacology130: 1606— 1612
47.
Schwarbe K. , Brosda J. , Wegener N. , Koch M. ( 2005) Clozapine enhances disruption of prepulse inhibition after sub-chronic dizocilpine- or phencyclidine-treatment in wistar rats. Pharmacology , Biochemistry and Behavior80: 213—219
48.
Seeman P. , Ko F. , Tallerico T. (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. MolPsychiat10: 877—883
49.
Swerdlow N.R. , Braff D.L. , Taaid N. , Geyer M.A. (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients . Arch Gen Psychiatry51: 139—153
50.
Swerdlow N.R. , Bakshi V. , Geyer M.A. (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats . J Pharmacol Exp Ther279: 1290—1299
51.
Swerdlow N.R. , Taaid N. , Ostwegel J.L. , Randolph E. , Geyer M.A. (1998) Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats . Behav Pharmacol9: 389—396
52.
Swerdlow N.R. , Braff D.L. , Geyer M.A. (2000) Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. BehaviouralPharmacology11: 279—269
53.
van Berckel B N M , Oranje B. , van Ree J.M. , Verbaten M.N. , Kahn R.S. (1998) The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behaviour in healthy human subjects . Psychopharmacology137: 271—281
54.
Varty G.B. , Higgins G.A. (1995a) Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs . Psychopharmacology122: 15—26
55.
Varty G.B. , Higgins G.A. (1995b) Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. EuropeanJournal of Pharmacology287: 201—205
56.
Wiley J.L. (1994) Clozapine's effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response . Pharmacology, Biochemistry and Behaviour49: 1025—1028
